Dmytro Boliukh

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Justin Stebbing, Y. Baranau, Valeriy Baryash et al. · The Lancet Oncology · 2017 · 123 citations · Full text

Medicine, Oncology, Breast Oncology +13

Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

Francisco J. Esteva, Y. Baranau, V. Baryash et al. · Cancer Chemotherapy and Pharmacology · 2019 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

Justin Stebbing, Y. Baranau, V. Baryash et al. · Breast Cancer Research and Treatment · 2021 · 21 citations · Full text

Medicine, Oncology, Pharmacology +17

Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).

Justin Stebbing, Y. Baranau, V. Baryash et al. · Journal of Clinical Oncology · 2017 · 13 citations

Medicine, Oncology, Pharmacology +17